A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status

A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status

Abstract Background Tumor progression and tumor response to anticancer therapies may be affected by activation of oncogenic pathways such as the antioxidant one induced by NRF2 (nuclear factor erythroid 2-related factor 2) transcription factor and the pathways modified by deregulation of oncosuppres...

Full description

Bibliographic Details
Main Authors: Alessia Garufi, Silvia Baldari, Riccardo Pettinari, Maria Saveria Gilardini Montani, Valerio D’Orazi, Giuseppa Pistritto, Alessandra Crispini, Eugenia Giorno, Gabriele Toietta, Fabio Marchetti, Mara Cirone, Gabriella D’Orazi
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
p53
NRF2
Curcumin
(arene)ruthenium(II) compound
Brusatol
Cancer therapy
Online Access:http://link.springer.com/article/10.1186/s13046-020-01628-5

Internet

http://link.springer.com/article/10.1186/s13046-020-01628-5

Similar Items